J&J’s Incivo Shows “Hints” Of Added Benefit, Says Germany’s IQWiG
This article was originally published in The Pink Sheet Daily
Executive Summary
IQWiG concludes that J&J/Vertex’s new Hep C drug Incivo might be helpful in certain patient groups, but the German HTA body questions the validity of a widely-used surrogate efficacy measure.